Triveni Bio
Triveni Bio is seeking a highly motivated and experienced Scientist to join the Biology and Translational Research team. This role involves leading image-based biomarker analyses and driving the experimental design and execution of cell-based and ex vivo preclinical models. The position offers an opportunity to shape the scientific biomarker strategy across multiple indications to advance therapeutics targeting novel disease pathways.
Triveni Bio is a clinical-stage biotechnology company taking a genetics-informed approach and leveraging advanced antibody engineering to develop first-in-class therapeutics for immune and inflammatory (I&I) diseases. The company's pipeline includes bispecific antibodies such as TRIV-573 and TRIV-509, targeting conditions like atopic dermatitis. Triveni's approach is rooted in human genetics and novel biology, aiming to redefine treatment paradigms for patients with uncontrolled inflammatory disease.
Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
Sep 23, 2025
Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis
May 21, 2025
Wilson Sonsini Advises Goldman Sachs Alternatives on Patent Matters Related to Series B Investment in Triveni Bio
Oct 18, 2024
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Triveni Bio.